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Cystic fibrosis (CF) is a lethal, monogenic disorder that af-
fects multiple organ systems of the body [1]. As per a Cystic
Fibrosis Foundation annual report, 60,000 to 70,000 peopleFTR, cystic fibrosis trans-
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s article under the CC BY-NC-ND lacross the world suffer from CF [2]. However, this estimate
is based on the data available from the existing registries in
developed countries (primarily the United States, Europe,
and Australia).
Symptoms in patients with CF include accumulation of
thick mucus, recurrent lung infections, persistent cough at
times associated with phlegm with or without hemoptysis,
wheezing, poor growth/weight gain (in spite of a good
appetite), frequent greasy, bulky stools or difficulty in
bowel movements, and electrolyte imbalance particularly
in countries with warm weather [3,4]. The estimated fre-
quency of CF per live birth in Caucasians is believed to be 1
in 2000e2500 children. Determining the precise magnitude
of prevalence of CF in South East Asian and Middle East
countries remains elusive. Though the prevalence of CF
has been estimated to fall in the range of 1 in 30,000 to 1
in 50,000, incidence of the disease has been reported in
the range of 1 in 2000 to 1 in 5800 live births (4e13). Basedentre (General Organization), Saudi Arabia. Production and hosting
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 Milestones of cystic fibrosis discovery in the Arab
countries.
Year
(reference)
Country Comment
1958 [5] Lebanon First CF in Arabs
1977 [6] Iraq First report
1981 [7] Kuwait After death
2:1056, 1/3500 birth/year
1984 [8] Jordan A pilot study (post-mortem)
1985 [9] Bahrain 19 incidence
1:5800, 80% consanguineous
marriages
1986 [10] Saudi Arabia First case report
1991 [11] UAE First report
2001 [12] Qatar In a large Bedouin family
48 H. Banjar, G. Angyalosion this, research suggests that these regions may harbor a
very large proportion of CF patients in the world [13]. As
per a recent report on extrapolated CF prevalence rates, it
is projected that 34,357 patients in India and 41,898 pa-
tients in China may have CF [13]. The high prevalence of
CF in these countries may be accountable due to the large
population (>1 billion) of these countries. These preva-
lence extrapolations for CF are only rough estimates
derived by applying the prevalence rates from the United
States (or a similar country) to the population of other
countries, and therefore may not reflect the actual prev-
alence of CF [13].
Similarly, determining the precise magnitude of the
prevalence of CF in the Middle East countries remains
difficult. Though the prevalence of CF has been estimated
to fall in the range of 1 in 2500e5000. Based on this, It is
projected that with a population of 27 million in Saudi
Arabia (14), and around 18 live birth/1000, at least
800e1000 cases may have CF (Table 1) [4e19]. These
prevalence extrapolations for CF are only rough estimates
and could be increased due to consanquinity (50% in the
general population and 85% in CF families) [4e19], and
therefore may magnify the actual prevalence of CF
(Table 1) [5e19].
The median survival in some Arab countries was esti-
mated to be from 10 to 20 years of age [4e19] for many
reasons such as: Delayed diagnosis due to decreased
awareness of the variable presentation of the disease. Un-
availabity of diagnostic tool such as quantitative sweat
chloride test (e.g in the city of Jeddah, Saudi Arabia, with 5
million dwellers, only two centers with proper sweat chlo-
ride measurement’s tool) [4e14]. Delayed institution of
treatment due to delayed referral to a specialized CF
center [4e19]. Early pseudomonas colonization at 3 years
compared to 7 years in the western countries [4e16]. Poor
compliance to treatment and chest physiotherapy, poor
distribution of CF specialized centers, Delayed nutritional
rehabilitation [4,16].
Even after more than 7 decades since CF is known, there
are many aspects of the disease which still remain enig-
matic [20]. The present review attempts to revisit various
facets of this disease and specifically highlights the most
important lacunae that exist in treating CF. Further, it aimsto emphasize the precarious consequences, if this disease is
ignored or left untreated. Therefore early diagnosis of the
disease is the important first step towards improved care.
In addition, this review also captures the steps toward
improvement of median survival in Arab countries.2. Pathophysiology of CF
Patients with CF inherit a defective gene in each chromo-
some (i.e. 2 defective copies) that encodes the protein “CF
transmembrane conductance regulator” (CFTR). The CFTR
gene, which is located on chromosome 7, spansw250 kB in
length, and translates into a protein of 1480 amino acids.
The protein is a mucosal surface chloride channel present
at the epithelial junctions and submucosal glands, and its
dysregulation/failure in anion transport causes the disease
manifestations [21e23].
Approximately 1800 known mutations have been iden-
tified for CF gene, which gives rise to disease phenotypes
[2]. Increasing attempts have been made to classify the
known mutations. Six different classes of mutations are
described based on the fate of the CFTR protein (Table 2
and Fig. 1). These reported gene defects lead to altered
protein synthesis such that there is insufficient, adequately
active CFTR at the cell surface. This causes the body to
secrete unusually thick and sticky mucus (Fig. 2).
The thick mucus clogs the lungs (pulmonary manifesta-
tion) leading to a vicious cycle of infection, inflammation,
and lung tissue destruction, ultimately leading to life-
threatening lung infections [21,22]. The secreted mucus
also clogs the pancreatic ducts, thereby obstructing the
flow of bile digestive enzymes (which help in digestion and
absorption of the food, especially of fats) to the small in-
testine. This leads to multitudes of disease conditions such
as pancreatic insufficiency, gall stones, cysts, and chronic
digestive problems (maldigestion and malabsorption)
[23e29]. In patients with CF, epithelial anion transport
fails, causing functional disruption in a number of organs
besides the airways, including the digestive system,
exocrine pancreas, gall bladder, reproductive tracts, and
the sweat ducts [21,23]. The types of complications in pa-
tients with CF largely depend on the degree and the type of
CFTR mutation.
Diagnosis: CF is typically diagnosed based on typical
clinical signs and symptoms and confirmed with high sweat
chloride test >60 mmol/liter and or CFTR detection of 2
pathogenic mutations [1e3]. Reports from a retrospective
study showed that diagnosis of CF in Saudi Arabia was done
based on the typical clinical symptoms and high sweat
chloride test [29]. In the past, newborn screening for
meconium albumin using the BM test strip was used in
Jordan to identify CF cases that were subsequently
confirmed using the sweat chloride test [30].
The most common CFTR described in the United States
and Europe is F508del, which constitutes 50%e85% of the CF
population (Table 2), whereas those described in the Middle
East were different due to consanguinity (Tables 3 and 4)
[26e36].
F508del presents in small numbers 10e20% in the Gulf
area, compared to 30e50 in North African countries
[26e36]. Novel mutations characterized most Arab
Table 2 Spectrum of most common mutations or genotype reported in the cystic fibrosis patients [21].
Class Effect % of CF
population
Mutations
1 Defective CFTR protein and does not reach the
cell surface
88.5% G542X
1717-8G->A
1898þ3A->G
711þ1G->T
W1282X
CFTRdel19
1609delCA
1782delA
936delTA
R1162X
Q890X
2 Total loss of protein because of incorrect
processing of CFTR
2.4% F508del N1303K 1507del R1066C
3 Deregulates the ion channel 4.4% D1270N G551D
4 Reduced ion fluxes and altered selectivity L206W D836Y R334W
P205S
R117H R347H
5 Functional proteins with normal chloride channel
activity but reduced rate of synthesis
2789þ5G->A 1811 þ 1,6 3849 þ 10kbC->T
6 Reduced expression of mutated CFTR protein
because of rapid removal from the apical
membrane
3272 þ 26G->A kbA->G
Figure 1 Overview of types of functional mutations in CFTR.
The road for survival improvement 49countries due to numerous communities (cosmopolitan)
especially in Lebanon [27], and Jordan [33]. Consanguinous
intermarriages in the Gulf area is high (80e96%) which was
expected to play a major factor in perpetuating many rare
mutations as in S549R in United Arab Emirates (UAE, 19%)
[26], (3849 þ 10KbC > T) in 26% in UAE [26], and (I1134V)
83% in Qatar [34].
In Saudi Arabia (Author’s personal experience) (Table 4),
reports in CFTR detection showed: 89% of CFTR alleles,
have been identified [28e31]. F508del constitutes 12% of
CFTR mutation. 1548 delG is the most common Saudi CFTR
mutation identified (20%). 1548 delG, F508del, I1234V,
3120þ1G > A, H139L, 711þ1G > A, N1303K, S549R,
2043delG, 1507del 9 are the most common CFTR mutations
of Saudi ethnic origin (80%). Screening for the previously
mentioned 10 mutations would identify 80% of C.F. alleles
(Table 4) [28e31].3. Strategies for treating CF
3.1. Currently established conservative therapies
for treating CF
The currently available therapies principally aim at main-
taining efficient lung function, clearing airways of mucus,
administering nutritional therapy (i.e. enzyme, multivi-
tamin, and mineral supplements) to maintain adequate
growth, and managing complications [37]. Although these
therapies have been highly successful in managing the
consequences of the gene defect, they are palliative in
nature.
Treatment guidelines have been developed in the
United States [38] and Europe [39], with the scope to
enhance care of CF patients, by sharing best practice. To
Figure 2 Comparison of normal vs defective epithelial fluid secretion in patients with cystic fibrosis.
Table 3 Important milestones in clinical and mutational findings in cystic fibrosis in the Middle East.
Country Year Authors (reference) No. of patients Major CFTR mutations
UAE 1994 Frossard et al. [26] 17 S549R
F508del
Lebanon 1997 Desgeorges et al. [27] 20 F508del W1282X
N1303K
Saudi Arabia 1997 El-Harith et al. [28] 15 3120þ1G/A
N1303K
1548delG
1998 Banjar et al. [29] 70 F508del
I1234V
N1303K
R553K
3120þ1G/A
2000 Kambouris et al. [31] 70 H139L
S549R
Palestine 1999 Cahana et al. [32] 70 3120 þ LKdel8.6kg
Jordan 2000 Rawashdeh [33] 202 F508del
Qatar 2001 Abdul Wahab [34] 29 I1234V
Bahrain 2002 Eskandarani [35] 19 2043delG
Tunisia 2005 Messadoud [36] 390 DF508, W1282, N1303K
Legend: NO- Number of patients, UAE- United Arab Emirates, CFTR- Cystic fibrosis transmembrane regulator.
50 H. Banjar, G. Angyalosithe authors’ knowledge, in the absence of regional or local
guidelines, in other regions these recommendations serve
as an example.
3.2. Gene therapy
The discovery of CFTR gene in 1989 spurred a great amount
of interest among the researchers [24]. It was reckoned
that replacement of CFTR gene during the neonatal period
before the onset of airway damage might provide the much
awaited cure to patients with CF [21]. However, effective
gene delivery with aerosolized adenovirus vector could not
be achieved due to the predominant presence of the
adenoviral receptor at the entry on the basolateral surface
of the epithelial cells [40].3.3. Potentiators and correctors
Potentiators are compounds that enhance the channel
gating characteristics of mutant CFTR via direct interaction
[24]. Potentiators function by increasing the amount of
time the CFTR channel is open, allowing for more Cl to
pass through the pores [24]. Despite the discovery of many
potentiators by high-throughput method, the precise
mechanism of action remains unclear [41]. Various clinical
trials are currently underway which in due course may
demonstrate the clinical benefits of these molecules in the
treatment of CF. Ivacaftor, a CFTR potentiator, has shown
efficacy and safety compared with placebo in CF patients
with a G551D mutation [42,43]. Ivacaftor is approved in
Europe, United States, and Canada for the treatment of CF
Table 4 Distribution of Common CFTR in KSA Total of 272 patients.
Mutation Type Exon/intron Pts % of total No. of
homoz
Homoz % of
þCFTR (230)
No. of
heteroz
Heteroz % of
þCFTR (230)
1 1548delG Novel Exon 10 47 20% 36 16% 11 5%
2 F508del Caucasian Exon 10 29 12% 28 12% 1 0.5%
3 I1234V African Exon 19 28 11% 28 12%
4 3120þ1G/A African/
Greek
Intron 16 24 10% 24 10%
5 H139L Novel Exon 4 21 9% 18 8% 3 1%
6 711þ1G/A Novel Intron 5 20 8% 16 7% 4 2%
7 N1303K European Exon 21 7 3% 7 3%
8 S549R UAE (France) Exon 12 7 3% 7 3%
9 2043delG Bahrain Exon 13 6 2% 5 2% 1 0.5%
10 1507del 9 Novel Exon 9 5 2% 5 2%
11 Others 36 15% 36 16%
12 Not Identified 11 5%
Total 241 100% 210 91% 20 9%
Legend: KSA- Kingdom of Saudi Arabia, Pts-number of Patients, No-number, Homoz- Homozgous, CFTR- Cystic fibrosis transmembrane
regulator gene mutations, Heteroz- Heterozygous.
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G551D mutation [42]. Ivacaftor treatment is not effective in
CF patients with homozygous F508del-CFTR mutation,
which is the most common mutation in Caucasian CF pa-
tients [44].
Similarly, compounds that correct the processing and
facilitate the movement of mutant F508 CFTR (primarily
class II mutations) out of the endoplasmic reticulum into
the apical plasma membranes of epithelial cells are termed
correctors. However, like the potentiators, the mechanism
of action of correctors remains unknown. Lumacaftor (VX-
809), an investigational corrector, has been shown to be
effective in enhancing CFTR function in patients with
F508del-CFTR [45]. A long-term phase III roll-over study of
treatment with lumacaftor in combination with ivacaftor is
ongoing; however, the study does not include CF patients
from the Middle East region [46]. Molinski et al studied the
molecular consequences of the c.3700 A > G (p.Ile1234Val)
mutation in CF, which is characterized by defective folding
and processing, similar to the F508del-CFTR [47]. Though
rare in the west, this mutation is relatively common in the
Middle East (12.3%) and is the second most common mu-
tation in some Middle East countries [26e36,47]. Molinski
et al hypothesized that the correction of the defective
protein through lumacaftor may have a significant impact
on medical treatment of CF in the Middle East.
3.4. Airways clearance
Congestion of the airways by viscous mucus is most common
in patients with CF [48]. Clearance of the clogged airways is
achieved by combination therapy that includes bronchodi-
lators, postural drainage, and chest physical therapy [37].
Several mucoactive drugs that affect the physical charac-
teristics or the quantity of mucus produced are known
which fall under 2 broad categories of mucolytics and
mucokinetics [49].
Dornase alfa, a recombinant human DNAse I, is a
mucolytic drug which provides potential benefits byreducing the adhesiveness and viscoelasticity of CF sputum
[50]. The results from clinical studies demonstrate that
aerosolized dornase alfa significantly improves lung func-
tion achieving a 6%e7% increase from baseline in forced
expiratory volume in 1 s (FEV1) after 6 months therapy
[51,52]. It has been reported that when the treatment is
stopped, the respiratory function deteriorates below their
previous values [53].
Hypertonic saline is a mucokinetic drug often been used
for improving lung function by mucus clearance [54]. It is a
highly concentrated salt solution (w7%) which increases
the ion concentration of airway surface liquid and osmoti-
cally draws fluid into the airway lumen. This results in
replenishment of fluid layer and accelerated mucus clear-
ance [55]. Inhaled/nebulized hypertonic saline has
demonstrated modest improvement in lung function and
reduction in pulmonary exacerbations without substantial
adverse events [56e58]. Few studies have demonstrated
improvements in respiratory function, the effects were
found to be transient, and therefore, predicted to be of
limited therapeutic benefit [59]. Some reports also
recommend the use of bronchodilators prior inhalation of
hypertonic saline to avoid transient narrowing of the air-
ways, coughing, and pharyngeal discomfort [60,61].
Mannitol dry powder (400 mg twice daily) is a recently
developed product with mucolytic effect through osmotic
mechanism. Mannitol is approved in Europe, for treatment
of adult CF patients (above 18 years of age) as an add-on
therapy to standard of care. In phase III trials it has
been shown that 26 weeks treatment with mannitol dry
powder improves lung function and reduces exacerbation
rates [62].
In addition to the use of mucoactive drugs, physicians
also recommend manual therapies/physiotherapy such as
postural drainage, percussion and vibration or breathing
through positive expiratory pressure device [60e63]. These
methods enable mucus clearance by accelerated expiratory
flow, reducing airway obstruction, and improving rheology
of mucus [64,65]. Patients are also advised to do regular
52 H. Banjar, G. Angyalosiphysical exercises in addition to chest physiotherapy from
an early age for efficient maintenance of respiratory
function. Increased physical exercise strengthens the res-
piratory muscles and also helps to clear the tenacious
mucus secretion that blocks the airways [66].
3.5. Bronchodilators
Bronchodilator treatment is the most commonly used
therapy being prescribed in w80% of patients with CF
[67e69]. Although bronchodilators are usually given to
overcome airways obstruction and hyper-responsiveness in
CF patients because of inhaled mucolytic and/or antibiotic
therapy, the response to inhaled bronchodilators is variable
both between and within patients [67e70]. However, long-
term studies failed to demonstrate sustained clinical ben-
efits [70]. Although their use in CF remains controversial,
EU and US guidelines recommend regular use of inhaled b2-
adrenergic bronchodilators to improve and maintain effi-
cient lung function, and also can be used before inhaled
antibiotics such as tobramycin and aztreonam [38,39,69].
3.6. Antibiotics in the treatment of CF
The significant improvement in the prognosis of CF can be
largely attributed to the arsenal of newer antibiotics that
combat with the pathogenic organisms [38,39]. Treatment
with specific antibiotic remains the mainstay of CF treat-
ment. It is highly recommended to be used in conjunction
with other therapies such as physiotherapy and treatment
with bronchodilators to promote clearance of the bronchial
mucus [38,39]. Patients with CF often present with recur-
rent infections with Haemophilus influenza (H. influenzae),
Staphylococcus aureus (S. aureus), and Pseudomonas aer-
uginosa (P. aeruginosa). H. influenzae and S. aureus are
usually the first pathogens encountered in childhood which
is later substituted by P. aeruginosa. An array of antibiotics
is usually prescribed to treat these bacterial infections.
However, the choice of antibiotics largely depends on the
presence of specific pathogen in the respiratory tract. It is
reported that overall 54.4% of the CF patients are infected
with P. aeruginosa [2]. Chronic infections with P. aerugi-
nosa result in rapid decline in lung function and increased
need for antibiotic treatment and hospitalization [71].
Therefore, treatment with effective antibiotic regimen
targeting this pathogen holds key in the successful man-
agement of CF. Aerosol antibiotics, such as colistin, tobra-
mycin, and aztreonam are recommended to be used as
regular maintenance therapy in the treatment of pseudo-
monas infection [38,39]. Although oral antibiotics (fluo-
roquinolones, amoxicillin, cephalexin, or trimethoprim)
may be prescribed for patients with less severe exacerba-
tions, P. aeruginosa related exacerbations are commonly
treated with combinations of intravenous (IV) antibiotics
for 1e3 weeks [25,38,39]. Despite frequent intravenous
therapy, patients often continue to present with deterio-
rating respiratory function and eventually succumb to lung
disease [72].
Inhaled antibiotics have been increasingly used to treat
persistent airway infection in people with CF. Treatment
with aerosolized antibiotics has been advocated for themanagement of the chronic P. aeruginosa infection. The CF
pulmonary guidelines published recently recommend the
use of aerosolized/inhaled tobramycin with or without
dornase alfa in the treatment of P. aeruginosa infections in
CF [38,39].
Tobramycin is an aminoglycoside antibiotic produced by
Streptomyces tenebrarius, and is indicated for the man-
agement of CF patients infected with P. aeruginosa [73]. It
primarily disrupts protein synthesis by bacteria, leading
to altered cell membrane permeability, progressive
disruption of the cell envelope, and eventual cell death
[74]. Tobramycin has demonstrated in-vitro activity against
a wide spectrum of gram-negative organisms including P.
aeruginosa.
Tobramycin is also available as a specifically developed
formulation for administration by nebulization. Evidence
from clinical and pharmacological studies have demon-
strated that tobramycin primarily concentrates in the air-
ways following administration [75]. Inhaled tobramycin
significantly improves lung function and reduces rate of
exacerbations in patients with CF. Inhaled tobramycin is
strongly recommended for chronic use in patients of 6
years of age with moderate-to-severe lung disease and with
P. aeruginosa persistently present in cultures of the airways
[38,39,76]. The quality of the evidence for the use of
inhaled tobramycin in patients with mild disease is limited
by the number of studies [38,39,58].
Macrolides antibiotics such as azithromycin are used at
anti-inflammatory doses to treat CF patients. However,
there is limited clinical evidence to support their use. A
clinical trial has shown that long-term use of azithromycin
in CF patients, 6 years of age, significantly reduced pul-
monary exacerbations and the number of additional courses
of oral antibiotics, irrespective of the infectious status [76].
Another randomized controlled trial demonstrated im-
provements in lung function after treatment with azi-
thromycin compared with placebo [77].
Maintenance therapy with long-term macrolides has
been proved to be beneficial in patients with CF [78].
However, long-term use of macrolides has shown evidences
of emergence of bacterial resistance in CF patients [79,80].
Of particular recent concern is the potential of increased
colonization of CF patients with nontuberculous mycobac-
teria [81].
3.7. Pancreatic enzyme therapy
Patients with CF and signs and symptoms of maldigestion
due to pancreatic insufficiency are usually prescribed with
pancreatic enzymes replacements to aid digestion [82]. It
has been reported that w15% of patients with CF possess
sufficient exocrine pancreatic function that enables normal
nutrient absorption [83]. Although studies endorse normal
pancreatic function in “pancreatic sufficient” CF patients,
quantitative assessment studies in these patients have
demonstrated impaired pancreatic ductal enzyme secre-
tions [84,85]. Pancreatic enzyme preparations of porcine
origin have been conventionally used to treat this type of
maldigestion. Most marketed enzyme preparations come in
special enteric-coated capsules that consist of desiccated
porcine pancreatic extracts [25].
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Besides the conservative treatment of CF, supplementation
with appetite-rich food is essential for improved functional
capacity and quality of life [86]. Nutritional supplementa-
tion particularly with fat-soluble vitamins A, E, K, and
sometimes D and minerals constitute an integral part of
treatment. The need for lipid-soluble vitamins can be
assessed directly by the measurement of vitamin A, D, E
levels [87].
4. Clinical implications of untreated CF
CF is a multi-manifestation disorder that affects respira-
tory, gastrointestinal, endocrine, sweat gland, and repro-
ductive systems [74]. Improper or non-treatment of
underlying disease may lead to several clinical implications.
4.1. Respiratory tract implications
Airways disease remains one of the worsening aspects in the
course of CF. Most of the morbidity and mortality associ-
ated with CF result from progressive lung disease, upper
airway infection, and chronic sinusitis [88]. CF patients
acquire lung infection, which triggers the onset of inflam-
matory cascade. The hallmark of CF lung disease is bron-
chiectasis. This paves the way for the establishment of
persistent infection by pathogens such as S. aureus, H.
influenzae, and P. aeruginosa ultimately resulting in
severely compromised airway defenses [53]. In few pa-
tients, diffuse bronchopulmonary disease is due to re-
fractory Burkholderia cepacia, which further makes
therapeutic management more cumbersome [88]. The
progression of airways disease in patients with CF leads to
eventual acute respiratory failure because of diffuse
bronchopulmonary disease, pneumonia, or acute hemop-
tysis [86]. Supporting this, a US study reported that inw80%
of patients with CF, cardiorespiratory complications are the
most common cause of death [89].
4.2. Pancreatic duct implications
The epithelial layers of the pancreatic ducts and the
gastrointestinal tract have abundant ion exchange channels
and CFTR levels similar to those found in the airway
epithelium [20,90]. In patients with pancreatic manifesta-
tions of CF, the pancreas is compromised at birth [20].
Concretion of pancreatic ducts by thick, viscid mucus
blocks digestive enzymes from entering the gut leads to
poor digestion and malabsorption of food [91]. Pancreatic
exocrine insufficiency contributes to growth retardation
and delayed puberty in children and low body weight in
adults [92]. It has been well documented that CF is the
major cause of pancreatic exocrine failure in early child-
hood. In adults, it is commonly associated with chronic
pancreatitis [92].
4.3. Gastrointestinal implications
Absence or abridged form of CFTR reduces fluid secretion in
the gut [20]. The intestinal content in these patientscontains minimal water content and becomes impacted.
This may result in meconium ileus at birth and distal in-
testinal obstruction syndrome later in life [93]. Altered or
malabsorption of the essential nutrients in the gut because
of lack of digestive enzymes causes the nutrients to be
excreted in the feces. This mainly leads to malnutrition and
retarded growth and development [77]. In addition, people
with CF experience other gastrointestinal symptoms
such as severe gastroesophageal reflux disease, intestinal
blockage by intussusception, and constipation [94].
Malnutrition is another common symptom in patients with
untreated or poorly controlled CF that affects growth and
reduces physical activity [95,96]. The prevalence of
malnutrition/hyponutrition in CF has been reported to be
high although it varies in different studies [97]. Negative
energy balance is considered as central to the development
of malnutrition [98].
4.4. Rectal prolapse in CF
Rectal prolapse is another clinical implication of CF (char-
acterized by protrusion of the rectal mucous membrane
through the anus) encountered in both pediatric and adult
patients [99]. The incidence of rectal prolapse is high
among male infants with CF than in adults with a peak
incidence between 1 and 3 years [99e102]. In a study re-
ported by Stern et al, rectal prolapse was found to occur in
18.5% of CF patients [97]. It further reported that though
rectal prolapse preceded diagnosis of CF, physicians rarely
appreciate its importance as a symptom of this disease
[103].
4.5. CF-related diabetes
Diabetes, referred to as CF-related diabetes (CFRD), is a
very common complication that develops over time in many
patients with CF [104] CFRD is distinct as it usually com-
bines the characteristics of both type 1 and type 2 diabetes
[104]. Reported prevalence of diabetes in children with
CF < 10 years of age is low. However, the prevalence in-
creases significantly with age, with 50% of patients devel-
oping CFRD by the age of 30 years [105]. Few studies have
demonstrated a plausible relationship between CFRD and
poor nutritional and respiratory status [106,107]. In pa-
tients with severely impaired insulin secretion, a more
rapid deterioration in the respiratory status is observed
[108]. Similar to rectal prolapse, the worsening in respira-
tory status may also predate the diagnosis of CFRD [109].
4.6. Implications of CF on liver
Complications of liver disease represent the third most
frequent cause of disease-related death in patients with CF
[77,110]. CF-associated liver disease is presently classified
among genetic cholangiopathies, which results because of
lack or dysfunction of the CFTR at the apical membrane of
bile duct cells [111]. Defective CFTR protein in a subset of
CF patients leads to thickened bile secretions. This further
chokes the bile ducts leading to liver and biliary compli-
cations [77,111]. Although the biliary tract manifestation is
usually clinically evident, the involvement of liver may only
54 H. Banjar, G. Angyalosibe apparent at the end stages [111]. Of the wide spectrum
of hepatobiliary complications, progression of focal biliary
cirrhosis to multilobular cirrhosis and potentially end-stage
liver disease is the most clinically relevant problem in pa-
tients with CF [112].
4.7. Implications on the reproductive system
More than 95% of males with CF are infertile. This infertility
is the result of obstructive azoospermia caused by malde-
velopment of the mesonephric ducts, resulting in either
agenesis or atresia of the epididymis, vas deferens, or
seminal vesicles [113,114]. Other factors that may com-
plement infertility in males with CF are the low serum
levels of vitamins A and E or interference with the normal
transport of the sperm [115]. Although not so frequent,
impaired fertility is also seen in females with CF. Infertility
characterized by thickened cervical mucus in females may
be a consequence of the presence of thick mucus in the
genital tract that barricades sperm penetration [114]. In
severe cases, malnutrition disrupts ovulation and causes
amenorrhea [116].
4.8. Socioeconomic implications of CF
CF poses significant financial burden on the patient and the
society on the whole [117]. Socioeconomic status remains
an important risk factor in CF management, as seen in many
chronic diseases, [118,119]. The following factors pro-
foundly impact the outcomes in CF patients: poor socio-
economic status, mental trauma in caregivers/patient,
employment status, and education.
5. Barriers in treating CF
Following are the few barriers that affect the treatment in
patients with CF.
5.1. Late diagnosis of CF
CF is detected with increasing frequency in older children,
adolescents, and even young adults [120]. The clinical
diagnosis of CF is often delayed because the early symp-
toms are minimal or nonspecific [120]. Considerable delays
in diagnosis of children with CF occur as the disease is
identified solely based on clinical presentation [120].
Another important reason responsible for protracted diag-
nosis of CF is lack of training among respiratory physicians
[13].
5.2. Adherence
Treatment adherence is crucial in patients with CF. Reasons
for poor adherence could be due to lack of access to care,
insufficient patient education, and high treatment burden.
Poor adherence is a notable problem, especially during
adolescence [121]. Poor adherence leads to serious conse-
quences, which includes increased morbidity and mortality,
reduced quality of life, and greater health care costs.
Although the rates of adherence to treatment for CF are
generally low, they vary significantly between the differenttypes of treatment [122]. The rates of adherence are
particularly poor in pediatric population than in adults with
CF. For example, the adherence rates for children with CF
are estimated to be 40%e47% for chest physical therapy
[123,124], whereas adherence to dietary recommendations
is even lower, ranging from 16% to 20% [125]. Briesacher
et al have shown that high adherence to inhaled tobramycin
solution is associated with a lower risk of hospitalization
and also leads to a lower outpatient service cost, than
patients with low adherence [126].
5.3. Limited number of CF testing centers in the
Middle East countries
Decreased access to care is another impediment that
adversely affects the health-related outcomes in many
patients with CF [118,119]. Further, the limited number of
dedicated CF diagnostic centers makes it one of the chal-
lenging diseases to treat [13]. The scenario can be well
visualized by an example that in a city like Riyadh, the
commercial capital of Saudi Arabia with 5 million dwellers,
has only 2 CF diagnostic centers [4e13,26e36,127].
5.4. Lack of proper medical care and patient
education
Therapeutic insufficiency is the main cause of precocious
complications and poor prognosis in patients with CF [128]. It
is now generally agreed that a team of trained experienced
health professionals in a specialist CF center with more than
50 patients can best provide this type of care. CF is a complex
disease with numerous medical, psychiatric, and social
consequences. For patients and their families, it means a
lifetime of adjustments. Lack of public awareness can make
the family feel isolated in its attempts to cope. Patients with
CF often need caregivers with the knowledge and sensitivity
to provide appropriate palliative care when required.
5.5. Cost and availability of pharmaceutical drugs
Management of CF is very expensive, with best survival
rates seen when patients are treated in specialized CF
centers. Costs of care increase with the age of patients,
mainly because of recurrent deteriorations in the lung
function and colonization with the pathogens such as P.
aeruginosa [129]. The majority of patients with CF are
often required to be on continuous medication to control
the unabated infections [117]. Apart from direct costs for
medication, laboratory analyses and costs of health care
visits further add to the economic burden [117].
5.6. Poverty
The links between poverty and CF are extensive, strong,
and pervasive. In spite of availability of sustainable treat-
ment options, people hardly utilize them because of their
exorbitant cost. People with CF and very poor affordability
are even unaware of the disease and are often deprived
quality treatment. In a disorder such as CF, with an equal
incidence in different social groups, a report suggested that
survival is strongly influenced by social factors [130].
The road for survival improvement 555.7. Improved therapies should be made available
The quality of life and longevity in patients with CF can be
prolonged if diagnosis of CF is established in the early
stages. This will enable initiation of appropriate thera-
peutic regimen to commence as soon as a diagnosis is made
[131]. Recent advancements have transformed CF from a
disease characterized by death in early childhood to a
chronic illness, with most patients living to adulthood.
Despite this progress, many patients with CF eventually
succumb primarily because of infection of the airways and
lung failure. There is still a lack of treatment modalities
that can offer complete cure. Hence, future research is
warranted to equip the biological arsenal so that CF-related
complications including deaths because of CF may be
significantly curtailed.
5.8. Recommendations
A holistic approach comprising of the following recom-
mendations may be appropriate in the treatment of CF:
Improve awareness of the disease, and its variable pre-
sentation, Early referral to CF specialized centers, make
the diagnostic sweat chloride test measurement to be
available in most major hospitals for most populated cities,
Early diagnosis and early institution of treatment, Early
nutritional rehabilitation, improve adherence to treatment
and air way clearance techniques, and to make most of the
CF drugs available to most CF centers.
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